Mega Lifesciences PCL (BKK:MEGA)

Market Cap	34.00B +27.9%
Revenue (ttm)	14.40B -3.1%
Net Income	2.07B +4.1%
EPS	2.37 +4.1%
Shares Out	871.87M
PE Ratio	16.45
Forward PE	14.32
Dividend	1.60 (4.16%)
Ex-Dividend Date	Mar 9, 2026

Volume	773,890
Open	38.50
Previous Close	38.50
Day's Range	38.25 - 39.00
52-Week Range	27.75 - 40.00
Beta	0.31
Analysts	Buy
Price Target	42.43 (+8.8%)
Earnings Date	Aug 13, 2026

About Mega Lifesciences PCL

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid’s, men’...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2025, Mega Lifesciences PCL's revenue was 14.19 billion, a decrease of -7.74% compared to the previous year's 15.39 billion. Earnings were 1.91 billion, a decrease of -4.99%.

Analyst Summary

According to 7 analysts, the average rating for MEGA stock is "Buy." The 12-month stock price target is ฿42.43, which is an increase of 8.80% from the latest price.

Price Target

฿42.43

(8.80% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error